Prothena Corporation PLC
prothena.comWhat Do They Do?
Develops investigational therapies targeting protein-related diseases, including Parkinson’s, Alzheimer’s and amyloid diseases, in collaboration with pharmaceutical companies.
10-K for FY2025, filed Feb 27, 2026Prothena Corporation plc (“Prothena” or the “Company”) is a late-stage clinical biotechnology company with expertise in protein…View ↗
Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a…View ↗
Our near-term plan is to continue to support our active clinical programs which are all partnered with large pharmaceutical companies…View ↗
How Do They Make Money?
Most revenue comes from pharmaceutical partners for research and development work billed over time, reimbursements, and milestone payments when programs reach clinical or regulatory steps. A smaller stream comes from sales of intellectual-property rights and milestones.
10-K for FY2025, filed Feb 27, 2026The Company’s collaboration revenue includes revenue recognized under the Company’s Collaboration Agreement with BMS as well as revenue…View ↗
Revenue is recognized only when the Company satisfies an identified performance obligation by transferring a promised good or service to a…View ↗
The Company generally classifies each of its milestones into one of three categories: (i) clinical milestones; (ii) regulatory and…View ↗
-
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗
$9.7M
-
10-K for FY2025, filed Feb 27, 2026
$9.7M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Collaboration revenue
|
99%
FY2022: 26%
|
Collaboration revenue, FY2025
$9.6M Sources
|
|
|
Revenue from license and intellectual property
Licensed
|
0.5%
FY2022: 74%
|
Revenue from license and intellectual property, FY2025
$50K Sources
|
Licensed |
Who Are Their Customers?
Roche and BMS contract directly with Prothena on collaborations; Novo Nordisk pays under arrangements tied to the ATTR amyloidosis business and related milestones.
10-K for FY2025, filed Feb 27, 2026
Do Revenues Turn Into Profits?
No. It lost $244.1M in FY2025.
10-K for FY2025, filed Feb 27, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$18.6MView ↗
- ▼ −85% (Loss)
- vs −$125.8M in Q2 FY2025
10-Q for Q2 FY2026, filed Aug 6, 2026
Open tableView ↗
-
Aug 6, 2026
Updates year-end cash guidance
The updated midpoint forecast is approximately $259 million in cash, cash equivalents and restricted cash.
Sources
8-K, filed Aug 6, 2026
Net cash used in operating and investing activities was $25.7 million in the second quarter, and net cash provided by operating and…View ↗
Shrinking. Revenue fell 95% in 4 years, from $200.6M in FY2021 to $9.7M in FY2025, about 53% a year.
A more partner-led clinical portfolio
The older report planned a fully integrated research, development and commercial business and included birtamimab for AL amyloidosis among its clinical programs. The latest report says all active clinical programs are partnered and describes a near-term focus on supporting them while investing in early research.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 27, 2026Our near-term plan is to continue to support our active clinical programs which are all partnered with large pharmaceutical companies…View ↗
Loading...
